Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZW0YO)

Drug Name

IM-023911 Drug Info

Synonyms

IM-023911; CHEMBL193342; AC1NQ014; A2595/0110399; MolPort-002-710-895; ZINC3672574; BDBM50173049; STK765418; AKOS001757037; MCULE-3428588247; 4-[4-[4-[chloro(difluoro)methoxy]anilino]phthalazin-1-yl]benzamide; 4-(4-{4-[chloro(difluoro)methoxy]anilino}-1-phthalazinyl)benzamide; 4-{4-[4-(Chloro-difluoro-methoxy)-phenylamino]-phthalazin-1-yl}-benzamide; 4-[4-({4-[chloro(difluoro)methoxy]phenyl}amino)phthalazin-1-yl]benzamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5187941
TTD Drug ID: DMZW0YO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[2]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[3]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[4]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[5]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[6]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[8]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[9]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[10]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8.
2	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
3	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
6	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
7	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
8	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
9	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
10	Clinical pipeline report, company report or official report of Exelixis (2011).
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services